Arcus Biosciences (RCUS) Net Cash Flow Growth (1y) (2018 - 2026)
Arcus Biosciences (RCUS) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 53.46% |
| 10 | Arcus Biosciences | 3.58 Bn | 2.76 Bn | - | -150.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.00% |
| Dec 31, 2025 | 68.63% |
| Sep 30, 2025 | -122.22% |
| Jun 30, 2025 | 293.10% |
| Mar 31, 2025 | -27.59% |
| Dec 31, 2024 | 10.53% |
| Sep 30, 2024 | 197.83% |
| Jun 30, 2024 | -262.50% |
| Mar 31, 2024 | 81.25% |
| Dec 31, 2023 | -375.00% |
| Sep 30, 2023 | 16.36% |
| Jun 30, 2023 | 97.10% |
| Mar 31, 2023 | -92.02% |
| Dec 31, 2022 | 62.29% |
| Sep 30, 2022 | 61.01% |
| Jun 30, 2022 | -301.39% |
| Mar 31, 2022 | 83.41% |
| Dec 31, 2021 | 33.59% |
| Sep 30, 2021 | -122.70% |
| Jun 30, 2021 | -131.56% |